Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan
Type I Diabetes
About this trial
This is an observational trial for Type I Diabetes focused on measuring Imaging, Type 1 Diabetes Mellitus (T1DM), Islet, B Cell Mass, Pet Scan, Type 1 Diabetes, T1DM, Pancreas, Healthy Volunteer, HV
Eligibility Criteria
INCLUSION CRITERIA Patients with T1DM inclusion criteria: Age greater than 18 History consistent with T1DM non-obese (BMI less than 35 kg/m(2)), and normal insulin sensitivity (as judged by insulin requirements less than or equal to 0.8 unit/kg/day). Low C-Peptide (less than or equal to 0.6 ng/ml) Pancreas Transplant Patient inclusion criteria: Age greater than 18 History consistent with T1DM (as above) PRIOR to pancreas transplant. Normal pancreas allograft function for at least the preceding 1 year. No acute rejection episodes within the past year. Control Patient inclusion criteria: Age greater than 18 No history of diabetes. Fasting blood glucose less than 100 mg/dl. Normal oral glucose tolerance. BMI less than 35 kg/m(2) Exclusion criteria for all: Liver dysfunction as determined by history, physical examination, and standard liver function testing (abnormal values for AST, ALT, Total/Direct Bilirubin, Alkaline Phosphatase) Coagulopathy Pregnancy Current breast feeding Use of MAO inhibitors or Levodopa Patients with a contraindication to MRI scanning.
Sites / Locations
- National Institutes of Health Clinical Center, 9000 Rockville Pike